Figure 6

Anti-CD47 triggers DC and T cell activation but does not affect NK phenotype. WT mice were injected once with AAV-PCSK9^DY and fed HCD for 10 weeks and treated with anti-CD47 mAb (MIAP410) for the last 4 weeks of the experiment (n = 9–10). Spleens from mice treated with control IgG (ctrl IgG) or anti-CD47 mAb (A). Quantification of spleen weight (B) and number of splenocytes (C). Percentage of SIRPα⁺CD11b⁺ DCs (D) and CD86 mean fluorescence intensity (E) of DCs. CD4⁺ and CD8⁺ T effector cells (F). CD90⁺ expression of NK cells in spleen, blood and liver (G). Levels of IFN-γ⁺ NK cells after stimulation with Brefeldin A or PMA/ionomycin/Brefeldin A (H). H&E and Prussian blue staining of spleens from WT and Cd47^−/− mice treated with control IgG or anti-CD47 (I). In vitro adhesion assay of WT or Cd47^−/− T cell binding to immobilized ligands SIRPα (K) and ICAM-1 (L) after pretreatment with control IgG, anti-LFA1 or anti-CD47 mAb (n = 3–5). *p < 0.05, **p < 0.01, ***p < 0.001.